Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy

Diabetes

Volumn 67, Issue 6, 2018, Pages 1182-1189

  Martinez, Robert ^a   Al Jobori, Hussein ^a   Ali, Ali M ^a   Adams, John ^a   Abdul Ghani, Muhammad ^a   Triplitt, Curtis ^a   DeFronzo, Ralph A ^a   Cersosimo, Eugenio ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CANAGLIFLOZIN; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; SULFONYLUREA; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY FAT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; STEADY STATE; TREATMENT DURATION; TREATMENT RESPONSE; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; COMBINATION DRUG THERAPY; DOWN REGULATION; DRUG EFFECT; HYPERGLYCEMIA; HYPOGLYCEMIA; METABOLISM; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SECRETION (PROCESS);

ADULT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON; GLUCAGON-SECRETING CELLS; GLUCONEOGENESIS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; LIRAGLUTIDE; MALE; MEMBRANE TRANSPORT MODULATORS; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85047772231     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db17-1278     Document Type: Article

References (33)

1. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 2017;13:11–26
2. Cersosimo E. Renal glucose handling and the kidney as a target for anti-diabetic medication. Curr Trends Endocrinol 2014;7:81–94
3. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124:509–514
4. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124: 499–508
5. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013;62: 3324–3328
6. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999;48:1198–1214
7. Lin HV, Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab 2011;14:9–19
8. DeFronzo RA, Andres R, Bedsoe TA, Boden G, Faloona GA, Tobin JD. A test of the hypothesis that the rate of fall in glucose concentration triggers counterregulatory hormonal responses in man. Diabetes 1977;26:445–452
9. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:1087–1095
10. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36:2508–2515
11. Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of b-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041–2047
12. Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015;95:513–548
13. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4:1004–1016
14. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 2017;19:1353–1362
15. Al Jobori H, Daniele G, Cersosimo E, et al. Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes. Diabetes 2017;66:1999–2006
16. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733–794
17. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512–517
18. Wang MY, Yu X, Lee Y, et al. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes. Proc Natl Acad Sci U S A 2017;114:6611–6616
19. Gustavson SM, Chu CA, Nishizawa M, et al. Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog. Metabolism 2004;53: 933–941
20. Cersosimo E, Zaitseva IN, Ajmal M. Effects of beta-adrenergic blockade on hepatic and renal glucose production during hypoglycemia in conscious dogs. Am J Physiol 1998;275:E792–E797
21. Kolodny EH, Kline R, Altszuler N. Effect of phlorizin on hepatic glucose output. Am J Physiol 1962;202:149–154
22. Cahill GF Jr. Starvation in man. N Engl J Med 1970;282:668–675
23. Krebs HA, Hems R, Gascoyne T. Renal gluconeogenesis. IV. Gluconeogenesis from substrate combinations. Acta Biol Med Ger 1963;11:607–615
24. Cersosimo E, Judd RL, Miles JM. Insulin regulation of renal glucose metabolism in conscious dogs. J Clin Invest 1994;93:2584–2589
25. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest 1995;96:2528–2533
26. Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism 1998;47:1227–1232
27. Cersosimo E, Molina PE, Abumrad NN. Renal lactate metabolism and gluconeogenesis during insulin-induced hypoglycemia. Diabetes 1998;47:1101–1106
28. Eid A, Bodin S, Ferrier B, et al. Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic fatty rats. J Am Soc Nephrol 2006;17:398–405
29. Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF Jr. Liver and kidney metabolism during prolonged starvation. J Clin Invest 1969;48:574–583
30. Cersosimo E, Garlick P, Ferretti J. Abnormal glucose handling by the kidney in response to hypoglycemia in type 1 diabetes. Diabetes 2001;50:2087–2093
31. DeFronzo RA, Ferrannini E, Hendler R, Wahren J, Felig P. Influence of hyper-insulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci U S A 1978;75:5173–5177
32. Ferrannini E, Wahren J, Felig P, DeFronzo RA. The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. Metabolism 1980;29:28–35
33. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669–672